GENEVA - The World Health Organization (WHO) warned countries with possible cases of the SARS-like novel coronavirus on Thursday that they must share information and not allow commercial labs to profit from the virus, which has killed 22 people worldwide.
WASHINGTON - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug compounding.
NEW BRUNSWICK, New Jersey - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
- Aveo Pharmaceuticals Inc said it was informed by its partner Astellas Pharma Inc that the Japanese company would not be seeking marketing approval for their experimental kidney cancer drug in Europe.
NEW YORK (Reuters Health) - Knee pain appears to decrease up to one year after "prolotherapy," a series of sugar water injections at the site of the pain, according to a new study.
LOS ANGELES - California unveiled prices on Thursday that consumers will pay for a selection of health plans offered through the state under the Affordable Care Act, providing a glimpse into how health care reform may look as it is rolled out across the nation.
NEW YORK (Reuters Health) - A web-based decision-making tool that alerts heart doctors when diagnostic tests would not be useful for a specific patient can curb wasteful procedures, according to a new study.
NEW YORK (Reuters Health) - People who had used marijuana in the past month had smaller waists and lower levels of insulin resistance - a diabetes precursor - than those who never tried the drug, in a new study.
NEW YORK (Reuters Health) - Women in their 40s didn't cut back on mammograms during 2010, the year after a government-backed panel said annual breast cancer screening should be optional for them, says a new study.
CHICAGO - U.S. scientists say a dramatic result last year suggesting that a cancer drug already approved by U.S. regulators could quickly clear out Alzheimer's plaques in mice was too good to be true.